• FirefoxUpgrade to the new Firefox »
  •  Dow Down1.39% Nasdaq Down1.38%

    Horizon Pharma plc (HZNP)

    -NasdaqGS
    16.66 Up 0.22(1.34%) 1:17PM EST - Nasdaq Real Time Price
    Add to Portfolio
    ProfileGet Profile for:
    Horizon Pharma plc
    Adelaide Chambers
    Peter Street
    Dublin, 8
    Ireland - Map
    Phone: 353 1 649 8521
    Website: http://www.horizonpharma.com

    Details 
    Index Membership:N/A
    Sector:Healthcare
    Industry:Drugs - Generic
    Full Time Employees:463

    Business Summary 

    Horizon Pharma plc, a specialty pharmaceutical company, through its subsidiaries, develops and commercializes medicines for the treatment of arthritis, pain, and inflammatory diseases. It offers ACTIMMUNE for reducing the frequency and severity of serious infections associated with chronic granulomatous disease; DUEXIS, a proprietary tablet formulation for the relief of signs and symptoms of rheumatoid arthritis (RA) and osteoarthritis (OA), and to decrease the risk of developing upper gastrointestinal ulcers in patients who are taking ibuprofen for these indications; and VIMOVO, a proprietary fixed-dose multi-layer delayed-release tablet for the relief of the signs and symptoms of OA, RA, and ankylosing spondylitis (AS). The company also provides RAYOS, a proprietary delayed-release formulation of low-dose prednisone for the treatment of moderate to severe active RA in adults when accompanied by morning stiffness, as well as for the treatment of polymyalgia rheumatica, psoriatic arthritis, AS, asthma, chronic obstructive pulmonary disease, and various other conditions. Horizon Pharma plc was founded in 2005 and is headquartered in Dublin, Ireland.

    Key Statistics


    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Horizon Pharma plc

    Corporate Governance 
    Horizon Pharma plc’s ISS Governance QuickScore as of Jan 1, 2015 is 8. The pillar scores are Audit: 5; Board: 5; Shareholder Rights: 8; Compensation: 7.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
     PayExercised
    Mr. Timothy P. Walbert , 48
    Chairman, Chief Exec. Officer and Pres
    1.03M0.00
    Dr. Jeffrey W. Sherman M.D., FACP, 60
    Chief Medical Officer and Exec. VP of R&D
    595.00K0.00
    Mr. Robert J. De Vaere , 57
    Consultant
    562.00K0.00
    Dr. Achim Schaffler Ph.D.,
    Co-Founder, Exec. VP of Manufacturing and Managing Director of Horizon Pharma GmbH
    N/AN/A
    Mr. Paul W. Hoelscher ,
    Chief Financial Officer and Exec. VP of Fin.
    N/AN/A
    Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders